Statistical considerations in clinical trial design of immunotherapeutic cancer agents

Journal of Immunotherapy

Volumn 38, Issue 7, 2015, Pages 259-266

  Dranitsaris, George ^a   Cohen, Roger B ^b   Acton, Gary ^c   Keltner, Llew ^f   Price, Melissa ^a   Amir, Eitan ^d   Podack, Eckhard R ^e   Schreiber, Taylor H ^a  

^a Heat Biologics Inc   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^f NONE

Author keywords

Checkpoint inhibitor; Clinical trial design; Immunotherapy; IrRC; Statistics; Vaccine

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOLOGIC FACTOR;

ARTICLE; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER STATISTICS; CANCER SURVIVAL; DRUG EFFICACY; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNE RESPONSE; LONG TERM SURVIVAL; NEOPLASM; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL ANALYSIS; STUDY DESIGN; THERAPY DELAY; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR IMMUNITY; UNITED STATES; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; METHODOLOGY; NEOPLASMS;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOLOGIC FACTORS; NEOPLASMS; RESEARCH DESIGN;

EID: 84942753071     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000089     Document Type: Article

References (36)

1. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-723.
2. Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32:1020-1030.
3. PD-1 inhibitors raise survival in NSCLC. Cancer Discov. 2014;4:6.
4. Chow LQ. Exploring novel immune-related toxicities and endpoints with immune-checkpoint inhibitors in non-small cell lung cancer. American Society of Clinical Oncology educational book/ASCO American Society of Clinical Oncology Meeting. 2013.
5. Antonia SJ, Larkin J, Ascierto PA. Immuno-oncology combinations: a review of clinical experience and future prospects. Clin Cancer Res. 2014;20:6258-6268.
6. Galon J, Mlecnik B, Bindea G, et al. Towards the introduction of the'Immunoscore' in the classification of malignant tumours. J Pathol. 2014;232:199-209.
7. Hoos A, Eggermont AM, Janetzki S, et al. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst. 2010;102:1388-1397.
8. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immunerelated response criteria. Clin Cancer Res. 2009;15:7412-7420.
9. Ananthakrishnan R, Menon S. Design of oncology clinical trials: a review. Crit Rev Oncol/Hematol. 2013;88:144-153.
10. US Food and Drug Administration document. Guidance for industry: clinical considerations for therapeutic vaccines. Available at: http://www.fda.gov/downloads/biologicsblood vaccines/guidancecomplianceregulatoryinformation/guidances/vaccines/ucm278673.pdf. Accessed March 5, 2014.
11. Weber JS, Kudchadkar RR, Yu B, et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol. 2013;31:4311-4318.
12. Stallard N, Whitehead J. Stopping rules for phase II studies. Br J Clin Pharmacol. 2001;51:523-529.
13. US Food and Drug Administration document. Guidance for industry: clinical trial endpoints for the approval of cancer drugs and biologics. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071590.pdf. Accessed March 3, 2014.
14. Sharma MR, Stadler WM, Ratain MJ. Randomized phase II trials: a long-term investment with promising returns. J Natl Cancer Inst. 2011;103:1093-1100.
15. US Food and Drug Administration document. Guidance for industry: statistical principles for clinical trials. Available at: http://www.fda.gov/downloads/Drugs/GuidanceCompliance RegulatoryInformation/Guidances/ucm073137.pdf. Accessed March 05, 2014.
16. Broglio KR, Berry DA. Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst. 2009;101:1642-1649.
17. US Food and Drug Administration document. Guidance for industry: adaptive design clinical trials for drugs and biologics. Available at: http://www.fda.gov/downloads/Drugs/y/Gui dances/ucm201790.pdf. Accessed March 05, 2014.
18. Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009;115:3670-3679.
19. Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010;28:1099-1105.
20. Goel MK, Khanna P, Kishore J. Understanding survival analysis: Kaplan-Meier estimate. Int J Ayurveda Res. 2010;1:274-278.
21. Chen TT. Statistical issues and challenges in immunooncology. J Immunother Cancer. 2013;1:1-9.
22. Hoos A. Evolution of end points for cancer immunotherapy trials. Ann Oncol. 2012;23(suppl 8):viii47-viii52.
23. Fine GD. Consequences of delayed treatment effects on analysis of time-to-event endpoints. Ther Innovation Regulatory Sci. 2007;41:535-539.
24. Royston P, Parmar MK. The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt. Stat Med. 2011;30:2409-2421.
25. Sanchez AM, Rountree W, Berrong M, et al. The External Quality Assurance Oversight Laboratory (EQAPOL) proficiency program for IFN-gamma enzyme-linked immunospot (IFN-gamma ELISpot) assay. J Immunol Methods. 2014;409:31-43.
26. Slota M, Lim JB, Dang Y, et al. ELISpot for measuring human immune responses to vaccines. Expert Rev Vaccines. 2011;10:299-306.
27. Butterfield LH, Palucka AK, Britten CM, et al. Recommendations from the iSBTc-SITC/FDA/NCI workshop on immunotherapy biomarkers. Clin Cancer Res. 2011;17:3064-3076.
28. Whiteside TL. Immune monitoring of clinical trials with biotherapies. Adv Clin Chem. 2008;45:75-97.
29. Yuan J, Ginsberg B, Page D, et al. CTLA-4 blockade increases antigen-specific CD8 (+) T cells in prevaccinated patients with melanoma: three cases. Cancer Immunol Immunother. 2011;60:1137-1146.
30. Yuan J, Adamow M, Ginsberg BA, et al. Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci U S A. 2011;108:16723-16728.
31. Schreiber TH. The use of FoxP3 as a biomarker and prognostic factor for malignant human tumors. Cancer Epidemiol Biomarkers Prev. 2007;16:1931-1934.
32. Wang L, Chang EW, Wong SC, et al. Increased myeloidderived suppressor cells in gastric cancer correlate with cancer stage and plasma S100A8/A9 proinflammatory proteins. J Immunol. 2013;190:794-804.
33. Fridman WH, Pages F, Sautes-Fridman C, et al. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12:298-306.
34. Klein O, Ebert LM, Nicholaou T, et al. Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4. Clin Cancer Res. 2009;15:2507-2513.
35. Freidlin B, Korn EL. Biomarker enrichment strategies: matching trial design to biomarker credentials. Nat Rev Clin Oncol. 2014;11:81-90.
36. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411-422.